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Abstract 
Background: Different studies have demonstrated the anti-inflammatory effects of human placental extract both 
in vivo and in vitro. Considering the chronic inflammatory nature of multiple sclerosis (MS) disease, we examined 
whether or not the administration of human placental extract is able to attenuate the neurological symptoms 
detected in experimental autoimmune encephalomyelitis (EAE) model of MS.
Methods: The injected myelin oligodendrocyte glycoprotein (MOG) induced EAE in mice, and treatment began from 
day 4 post-injection by intraperitoneal administration of 0.2 mg/kg human placental extract, repeated every other 
day up to day 31 post-injection. At the end of the treatment, luxol fast blue (LBS) staining and hematoxylin and eosin 
(H&E) staining were performed to evaluate the demyelination of neurons and inflammatory responses, respectively. 
Further assessed were the serum concentrations of IL-23 and IL-27.
Results: The administration of human placental extract was able to significantly reduce the mean clinical score in 
EAE mice, decrease the pro-inflammatory process and attenuate neural demyelination. Moreover, while the serum 
concentration of IL-23 was significantly diminished in the EAE mice receiving human placental extract compared to 
the non-treated EAE group, IL-27 concentration was significantly increased.
Conclusions: Our findings demonstrated the administration of human placental extract could significantly attenuate 
the neurological symptoms in the EAE model of MS in part through modulating the serum levels of IL-23 and IL-27 
and enhancing neuroprotection and myelin repair.
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Background
Characterized by the progressive demyelination of neu-
rons, multiple sclerosis is the most prevalent chronic 
inflammatory disorder of the nervous system, affecting 
more than 2 million individuals worldwide [1]. Among 
different pro-inflammatory mediators identified in the 
central nervous system (CNS), those related to interleu-
kin-12 (IL-12) cytokine family containing IL-12, IL-23, 
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with the etiology of MS. While the pro-inflammatory 
nature of IL-12 and IL-23 cytokines has been elucidated 
in several studies, additional anti-inflammatory proper-
ties have been attributed to IL-27. Consistently, it has 
been shown that the continuous administration of IL-27 
in experimental autoimmune encephalomyelitis (EAE) 
model can significantly reduce the severity of the dis-
ease in animals [2–4]. Furthermore, knockout mice for 
IL-27 receptor or its downstream signaling mediators 
develop EAE disease with much more severe symptoms 
in comparison to normal mice [5, 6]. Based on transla-
tional studies performed on human, treating dendritic 
cells obtained from healthy donors, with IFN-β promotes 
secretion of IL-27 in vitro [7]. Similarly, ex vivo isolated 
plasmacytoid dendritic cells (pDCs) obtained from MS 
patients receiving IFN-β treatment for a period of one 
month, secreted higher amounts of IL-27 compared to 
the non-treated group [8]. Also, patients demonstrat-
ing good response to glatiramer acetate therapy also had 
elevated serum levels of IL-27 [9]. All these observations 
confirm the anti-inflammatory role of IL-27 in CNS auto-
immunity, proposing it as a valuable target for treating 
MS. On the contrary, IL-23 exacerbates the demyelina-
tion of neurons through promoting the differentiation 
and maturation of Th17 cells. These cells are believed to 
be the key contributors in the development of encepha-
litogenic responses [10]. Therefore, any medication capa-
ble of increasing the serum concentration of IL-27, while 
decreasing IL-23, can be considered as a potential ther-
apy for MS.
Human placenta is believed to encompass numer-
ous biological molecules with a broad range of biologi-
cal activities [11–13]. Different studies have shown that 
human placenta and its extract are able to modulate 
immune responses, protect and regenerate hepatocytes, 
regulate hormonal balance in women’s body, modu-
late monoamine oxidase activity in brain, and promote 
wound healing and the anti-coagulation process [14–19]. 
In line with these observations, different types of growth 
factors, their corresponding receptors, and other regulat-
ing molecules have been recognized in human placenta 
[20–24]. Currently, human placental extract is approved 
for clinical use to improve chronic liver dysfunction 
and alleviate menopausal symptoms in different coun-
tries [16, 25]. Along with these findings, the immuno-
inhibitory function of human placental extract has been 
proven in numerous studies. For instance, it has been 
shown that the administration of placental extract in 
lymphocytes results in a cytostatic response and inhibi-
tion of responses to mitogenic stimuli [26]. In addition, 
by affecting T lymphocytes, placental extract is capa-
ble of inhibiting graft-versus-host disease and allogenic 
mixed lymphocyte reaction [27, 28]. Placental extract 
may further inhibit B cells activity because the secretion 
of antibody against immunized antigen is suppressed in 
the presence of placental extract [29]. Also, the suppres-
sive effect of placental extract on inflammation caused 
by pro-inflammatory agents such as carrageenan is rep-
resentative of its inhibitory effect on innate immune sys-
tem [14]. Finally, from a clinical point of view, placental 
extract is applied in the treatment of pelvic inflammatory 
disease [30].
Based on such observations, we hypothesized that the 
immunomodulatory effects of human placental extract 
might be conducive to attenuating neurological symp-
toms in association with EAE model of MS. Therefore, 
in the current study, we demonstrated the protective 
impacts of human placental extract on the EAE model of 
MS. In addition, as Il-23 and IL-27 are the main modula-
tors of inflammation in MS, the modulatory effects of the 
extract on these cytokines were also examined.
Methods
Animals
Adult female C57BL/6 mice (18–20  g in weight) were 
obtained from Pasteur institute of Iran (Tehran, Iran) and 
housed 4 per cage under a 12 h light/dark cycle at room 
temperature. Whole Experimental procedures was per-
formed according to the NIH’s guidelines for the care and 
use of laboratory animals, which was approved by the 
Ethics Committee for Animal Research of Iran University 
of Medical Sciences, Tehran, Iran.
Induction and treatment of EAE
EAE was induced by subcutaneous injection of 400  μg 
 MOG35–55 peptide, emulsified in complete Freund’s adju-
vant (Sigma Alderich) holding Mycobacterium tuberculo-
sis with a concentration of 5  mg/ml to the symmetrical 
points in the left and right flanks of C57BL/6 mice on 
day zero. On the same day, mice were intra-peritoneally 
injected with 250  ng pertussis toxin (Sigma Alderich) 
dissolved in 200 μL saline (i.p.), repeated 48 h later. On 
a daily basis, the clinical symptoms associated with the 
disease were evaluated, and the mice were weighed, and 
scoring was performed according to the following estab-
lished protocol: 0, no symptoms; 1, decreased or loss of 
tail tonicity; 2, flabby tail; 3, paralysis in one hind limb; 
4, paralysis in both hind limbs; 5, paralysis of hind limb 
and the forelimb; and 6, death [31]. A facilitated route 
was also provided for the easy access of paralyzed mice to 
both water and food. At the beginning of the study, mice 
were randomly classified into three groups, each consist-
ing of 5–6 mice which received the following treatments:
Group I (control group): mice in this group were all 
healthy (EAE was not induced) and only received vehicle 
(PBS) as treatment.
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Group II (EAE negative control group): EAE was 
induced in these mice and treatment only consisted of 
PBS injection.
Group III (Human placental extract-treated EAE 
group): EAE was induced in these mice and treatment 
consisted of injecting 0.2 mg/kg human placental extract 
IP.
Treatments, either with PBS or Human placental 
extract, were administered every other day commencing 
from day 4 and ending on day 31. Body weight recording 
and EAE clinical scoring were also evaluated up to the 
end of day 31. On the following day, all mice were eutha-
nized and spinal cord and brain tissues were collected for 
further histopathological analysis by luxol fast blue and 
H&E staining.
Tissue preparation, luxol fast blue and H&E staining
Methods applied in this section of study are similar to 
those reported by Mozafari et  al. [32]. Following anes-
thetization, mice were intracardially perfused with 0.1 M 
PBS, and then with 4% paraformaldehyde in 0.1  M PBS 
(pH 7.4). Thereafter, Lumbar spinal cords were collected 
and subjected to post-fixation overnight at 4  °C. The 
extent of demyelination was evaluated using luxol fast 
blue (LBS) staining while hematoxylin and eosin (H&E) 
staining was performed to the count the number of 
inflammatory cells and vacuolization.
For LBS, tissue samples were initially dehydrated in a 
series of alcohol concentrations and then cleared by incu-
bating in xylene. Processed samples were then paraffin-
embedded, blocked and sectioned into pieces of 5  μm 
in diameter utilizing rotary microtome (Lieca Microsys-
tems, UK). Each section was rehydrated separately and 
stained for 3  h with 0.1% Luxol Fast Blue (British Drug 
House, UK) at 60 °C. Counterstaining was performed for 
5  min using 0.1% Cresyl Fast Violet (Merck, Germany). 
Following the second step of dehydration and clearance 
with alcohol and xylene, sections were cover slipped and 
thoroughly screened for to identify demyelinated lesions 
using an Olympus BX-51 microscope. Upon the identi-
fication of a lesion site, 7 sections within the 40–50 μm 
interval were selected for quantitative analysis. Totally, 
21 slides were evaluated in each group (n = 3) and mye-
lin staining severity and extent of the demyelinated area 
were quantified utilizing ImageJ software (version 1.32j, 
NIH, USA). The extent of demyelination was reported as 
percentage of the total area. To calculate the myelination 
intensity, the myelin density stained inside the demy-
elinated area was normalized to the one observed in an 
intact region in the same section. It was performed fol-
lowing rehydration in alcohol concentration series and 
paraffin embedment. Staining was then performed with 
hematoxylin for 4  min and counterstaining was done 
with eosine for 1.5  min. Sections were then thoroughly 
washed, cover slipped and analyzed by an expert patholo-
gist blinded to the identity of the groups. A total of 21 
sections were obtained from each experimental group 
and analyzed by a pathologist to specify the number of 
presented inflammatory cells and vacuolization.
Measurement of the serum levels of IL‑23 and IL‑27
At the end of the study (day +31), mice blood was col-
lected by cardiac puncture and the collected sera were 
used to identify the application of the commercially 
available enzyme-linked immunosorbent assay (ELISA) 
related to the manufacturers protocol (Bioscience, UK).
Statistical analysis
Data obtained from histological analysis, the serum con-
centrations of IL-23 and IL-27, and the total number of 
clinical scores in three groups were analyzed with the 
graph pad/Prism version 8 using one-way ANOVA, fol-
lowed by Tukey–Kramer post-test. All experiments were 
represented in the form of Mean ± SD (standard devia-
tion). Throughout the study, p  values lower than 0.05 
were regarded as statistically significant.
Results
Human placental extract treatment attenuated EAE
Figure  1 represents the clinical grade of EAE as a func-
tion of time for different groups. In both the control and 
human placental extract groups, clinical symptoms were 
commenced on day +12. However, the maximum mean 
clinical score (MMCS) of the treatment group receiv-
ing human placenta extract (1.32 ± 0.21) was signifi-
cantly lower than the normal group (P < 0.0001), hence 
the conclusion that treatment with human placental 
extract can significantly attenuate the severity of EAE 
symptoms. Based on the histopathological studies per-
formed on lumbar spinal cords isolated from the mice at 
the end of the study, a significantly reduced demyelina-
tion was observed following treatment with human pla-
cental extract compared to PBS-receiving group (Fig. 2). 
In addition, while the intensity of myelin was reduced in 
PBS treatment group, human placental extract was able 
to enhance myelin staining intensity.
The effect of human placental extract on the body weight
Figure 3 shows the effect of human placental extract on 
body weight of EAE mice in comparison to other groups 
including control negative and PBS receiving during 
the treatment period. In PBS receiving EAE mice, the 
mean body weight at the end of the treatment period 
(day 31) was significantly lower than the normal control 
group (P = 0.027). However, administration of human 
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placental extract could significantly lower the trend of 
body weight loss in EAE mice; however, regarding this 
trend, no significant differences were observed between 
human placental extract receiving group and normal 
control group at the end of the treatment period. No 
significant toxicities related to the administration of 
human placental extract administration was observed 
throughout the survey period.
The effect of human placental extract on leukocyte 
infiltration into CNS
Figure 4 shows the effect of human placental extract on 
leukocyte infiltration into CNS as compared with other 
groups, including control negative and PBS receiving 
groups at the end of the treatment period. According to 
Fig. 5, a severe CNS inflammation was observed in EAE 
mice receiving PBS compared to the normal control 
group. Interestingly, a significantly lower CNS inflamma-
tory pattern was observed in mice treated with human 
placental extract. Therefore, it can be concluded that 
human placental extract can significantly inflammatory 
process in EAE mice.
Effect of human placental extract on the expression profile 
of IL‑23 and IL‑27
Figures  6 and 7 demonstrate the serum concentra-
tions of IL-23 and IL-27 in normal control and EAE 
treated and non-treated with human placental extract. 
In the normal group, the mean plasma concentra-
tions for IL-23 and IL-27 were 14.52 ± 2.126 and 
20.3 ± 5.045, respectively. In EAE mice receiving PBS, 
the concentration of IL-23 was significantly increased 
(26.15 ± 4.747; p = 0.0036), while IL-27 was signifi-
cantly reduced (3.12 ± 1.10; p = 0.0027). Although the 
administration of human placental extract was not 
able to restore the serum concentrations of IL-23 and 
IL-27 to the normal state, IL-23 concentration was sig-
nificantly decreased (20.63 ± 3.645; p = 0.0036), while 
Fig. 1 Evaluation of symptom severity scores in different groups showed that treatment with placenta extract significantly improved in this group 
(P = 0.0185)
Fig. 2 Diagram of clinical signs after human placenta extract 
administration. Treatment with human placental extract can 
significantly attenuate the severity of EAE symptoms
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the concentration of IL-27 was significantly increased 
(30.18 ± 16.06; p = 0.0027) compared to the EAE mice 
receiving PBS. These results further corroborate the 
anti-inflammatory role of human placental extract in 
EAE mice.
Discussion
Different studies have investigated the effects of vari-
ous anti-inflammatory substances in the mouse mod-
els of multiple sclerosis [33, 34]. We also examined the 
anti-inflammatory effects of gold nanoparticles in a 
Fig. 3 For statistical analysis of weight changes of mice after calculating the weight loss of each mice at the end of the period, statistical analysis 
of data was performed to compare groups weight loss with each other. There was a significant increase in weight changes in the treated group 
(p = 0.0222)
Fig. 4 H&E staining converter; a, b of normal group (transverse section), c, d of normal group (longitudinal section), e, f of EAE group (longitudinal 
section), form g and h of treated group (longitudinal section). The presence of inflammatory areas and inflammatory cells infiltrated into the spinal 
cord tissue in the EAE group was observed in the EAE group compared to the normal group, with a decrease in inflammatory cells in the treated 
group
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mouse model in a previous study, which revealed the 
anti-inflammatory effects of gold nanoparticles in the 
EAE mouse model [35, 36]. In the present research, the 
Fig. 5 LFB staining of the longitudinal spinal cord. a, b There are no demyelination areas during the spinal cord of the healthy group. c, d Presence 
of demyelination areas during the spinal cord of the EAE group. e, f Significant reduction of the demyelinated areas during the spinal cord of the 
treatment group
Fig. 6 Diagram of IL-23 ELISA test results in placenta extract treated 
groups. IL-23 concentration was significantly decreased (p = 0.0036), 
compared to the EAE mice receiving PBS
Fig. 7 Diagram of IL-27 ELISA test results in placenta extract treated 
groups. Concentration of IL-27 was significantly increased (p = 0.0027) 
compared to the EAE mice receiving PBS
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administration of human placental extract in EAE mice 
could improve clinical symptoms associated with EAE, 
in part attributable to the immunomodulatory effects of 
human placental extract on hyper activated immune sys-
tem of EAE mice. The anti-inflammatory consequence 
of human placental extract has also been indicated in 
both in  vitro and in  vivo models of inflammation. For 
instance, treatment of LPS-stimulated RAW264.7 mouse 
macrophages with human placental extract resulted in 
a significant reduction in the section of TNF-α, IL-1β 
and IL-6 and other inflammatory mediators such as NO 
from these cells [37]. Therefore, the mechanism under-
lying the anti-inflammatory effects of human placental 
extract may partly be mediated through suppressing the 
expression of pro-inflammatory cytokines. Similarly, in 
the carrageenan-induced rat paw edema model of inflam-
mation, administration of human placental extract could 
attenuate the swelling of rat’s paw [38]. Human placen-
tal extract is also able to inhibit granuloma formation 
in animal models of sub chronic inflammation. Finally, 
the administration of human placental extract in ani-
mal models of chronic inflammation, including rat AIA 
(Adjuvant-Induced Arthritis) model, could significantly 
attenuate inflammatory reactions [38]. The attenuation 
of neural demyelination evident in H&E and LBS stained 
sections, as well as the suppression of immune cells infil-
tration into the CNS further confirm the anti-inflamma-
tory behavior of human placental extract in EAE mice. It 
has been shown that autoreactive CD4 + T-lymphocytes, 
especially Th17 cells, followed by Th1 and CD8 + , are the 
main players in the development of MS and the process 
of neural demyelination [39]. Therefore, human placental 
extract must be partly effective in attenuating destructive 
effects observed in these cells. The precise mechanism of 
the anti-inflammatory effects of human placental extract 
is yet to be fully elucidated; however, based on the fore-
going observations, it can be concluded that: (A) human 
placental extract can partly affect NF-kB and inhibit the 
secretion of pro-inflammatory cytokines and media-
tors, and (B) human placental extract can attenuate the 
activity of T-cells because the demyelination of neurons 
mainly take place as a consequence of the destructive 
activity of these cells on neural cells myelin.
In parallel, perhaps the most important finding of our 
study was the modulatory effects of human placental 
extract on the serum levels of IL-23 and IL-27. As men-
tioned earlier, the serum level of IL-23 is usually higher 
and, in most cases, IL-27 is lower in MS patients com-
pared with normal subjects, hence potential response 
modifiers for MS immunotherapy [40, 41]. For the first 
time, the present study showed that human placental 
extract was able to significantly increase the concentra-
tion of IL-27 (a cytokine which high concentration in 
the serum of MS patient results in good prognosis), and 
decrease IL-23 (a pro-inflammatory cytokine associated 
with poor prognosis in MS patients). Thus, another pro-
tective effect of human placental extract against EAE may 
be attributed to the modulation of the balance between 
IL-23 and IL-27 serum concentrations. Given the ability 
of IL-23 to promote the secretion of IL-10 and regulate 
IL-17 production by CD4 + T cells [42], one may pro-
pose that the administration of human placental extract 
in the first place, may suppress the destructive activity of 
autoreactive T cells in EAE. Similarly, human placental 
extract can suppress the secretion of several pro-inflam-
matory mediators, including IL-23 and several other 
mediators mentioned in different studies, resulting in the 
attenuation of inflammation and the mean clinical score 
in EAE mice [43–45].
Conclusions
Although, more evaluations are needed, the results 
of the current study display the protective effects of 
human placental extract in the EAE model of MS which 
may partly be mediated through the downregulation of 
the serum levels of IL-23, upregulation of IL-27. Thus, 
human placental extract may be considered as a putative 
therapeutic agent for the management of clinical features 
observed in MS.
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